Study features and baseline and follow-up characteristics of cohort members who were nondiabetic at the baseline examination, SAHS, MCDS, and IRAS
| Variable . | SAHS (7.5-years follow-up)* . | . | MCDS (6.5-years follow-up)* . | IRAS (5-years follow-up)* . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| . | NHW . | HA . | MX . | NHW . | AA . | HA . | |||
| n | 549 | 1039 | 1,336 | 277 | 224 | 149 | |||
| M/F (%) | 45.5/54.5 | 40.5/59.5 | 41.8/58.2 | 49.8/50.2 | 39.3/60.7 | 45.0/55.0 | |||
| NGT/IGT (%) | 91.6/8.4 | 84.4/15.6 | 90.0/10.0 | 67.5/32.5 | 66.5/33.5 | 68.5/31.5 | |||
| Age (years) | 43.8 ± 10.6 | 43.1 ± 10.7 | 46.0 ± 8.1 | 55.3 ± 8.4 | 54.2 ± 8.7 | 53.8 ± 8.7 | |||
| Body weight (kg) | 75.8 ± 16.1 | 75.1 ± 15.7 | 68.6 ± 11.2 | 80.3 ± 15.6 | 83.1 ± 17.0 | 72.8 ± 14.7 | |||
| BMI (kg/m2) | 26.1 ± 4.6 | 28.5 ± 5.6 | 27.9 ± 4.2 | 27.5 ± 5.0 | 29.0 ± 5.6 | 27.3 ± 4.7 | |||
| Fasting glucose (mg/dl) | 84.8 ± 11.0 | 86.1 ± 10.2 | 84.0 ± 11.7 | 98.6 ± 10.7 | 99.8 ± 10.7 | 94.6 ± 9.9 | |||
| 2-h glucose (mg/dl) | 97.3 ± 31.1 | 108.2 ± 32.2 | 101.3 ± 29.0 | 122.5 ± 33.0 | 125.1 ± 33.2 | 120.4 ± 33.8 | |||
| Fasting insulin (IU/ml) | 11.3 ± 12.6 | 14.5 ± 14.7 | 15.2 ± 14.1 | 17.1 ± 12.5 | 18.9 ± 10.9 | 18.9 ± 12.6 | |||
| 2-h insulin (lU/ml) | 66.0 ± 75.3 | 102.1 ± 96.8 | 91.4 ± 77.6 | 76.9 ± 73.6 | 97.2 ± 78.1 | 99.4 ± 82.2 | |||
| Triglycerides (mg/dl) | 128.2 ± 98.5 | 146.4 ± 97.6 | 203.0 ± 140.7 | 136.0 ± 80.7 | 100.0 ± 53.5 | 151.7 ± 94.9 | |||
| Mean follow-up time (year) | 7.6 ± 0.4 | 7.4 ± 0.4 | 6.4 ± 0.5 | 5.3 ± 0.3 | 5.3 ± 0.4 | 5.2 ± 0.3 | |||
| Cumulative diabetes incidence (%) | 6.6 | 13.0 | 4.8 | 16.6 | 16.5 | 16.8 | |||
| Variable . | SAHS (7.5-years follow-up)* . | . | MCDS (6.5-years follow-up)* . | IRAS (5-years follow-up)* . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| . | NHW . | HA . | MX . | NHW . | AA . | HA . | |||
| n | 549 | 1039 | 1,336 | 277 | 224 | 149 | |||
| M/F (%) | 45.5/54.5 | 40.5/59.5 | 41.8/58.2 | 49.8/50.2 | 39.3/60.7 | 45.0/55.0 | |||
| NGT/IGT (%) | 91.6/8.4 | 84.4/15.6 | 90.0/10.0 | 67.5/32.5 | 66.5/33.5 | 68.5/31.5 | |||
| Age (years) | 43.8 ± 10.6 | 43.1 ± 10.7 | 46.0 ± 8.1 | 55.3 ± 8.4 | 54.2 ± 8.7 | 53.8 ± 8.7 | |||
| Body weight (kg) | 75.8 ± 16.1 | 75.1 ± 15.7 | 68.6 ± 11.2 | 80.3 ± 15.6 | 83.1 ± 17.0 | 72.8 ± 14.7 | |||
| BMI (kg/m2) | 26.1 ± 4.6 | 28.5 ± 5.6 | 27.9 ± 4.2 | 27.5 ± 5.0 | 29.0 ± 5.6 | 27.3 ± 4.7 | |||
| Fasting glucose (mg/dl) | 84.8 ± 11.0 | 86.1 ± 10.2 | 84.0 ± 11.7 | 98.6 ± 10.7 | 99.8 ± 10.7 | 94.6 ± 9.9 | |||
| 2-h glucose (mg/dl) | 97.3 ± 31.1 | 108.2 ± 32.2 | 101.3 ± 29.0 | 122.5 ± 33.0 | 125.1 ± 33.2 | 120.4 ± 33.8 | |||
| Fasting insulin (IU/ml) | 11.3 ± 12.6 | 14.5 ± 14.7 | 15.2 ± 14.1 | 17.1 ± 12.5 | 18.9 ± 10.9 | 18.9 ± 12.6 | |||
| 2-h insulin (lU/ml) | 66.0 ± 75.3 | 102.1 ± 96.8 | 91.4 ± 77.6 | 76.9 ± 73.6 | 97.2 ± 78.1 | 99.4 ± 82.2 | |||
| Triglycerides (mg/dl) | 128.2 ± 98.5 | 146.4 ± 97.6 | 203.0 ± 140.7 | 136.0 ± 80.7 | 100.0 ± 53.5 | 151.7 ± 94.9 | |||
| Mean follow-up time (year) | 7.6 ± 0.4 | 7.4 ± 0.4 | 6.4 ± 0.5 | 5.3 ± 0.3 | 5.3 ± 0.4 | 5.2 ± 0.3 | |||
| Cumulative diabetes incidence (%) | 6.6 | 13.0 | 4.8 | 16.6 | 16.5 | 16.8 | |||
Indicates follow-up period of the individual cohorts (total n = 3,574, 343 events over 23,805 person-years of follow-up). Data are proportions or mean ± SD. AA, African American; HA, Hispanic American; MX, Mexican; NHW, non-Hispanic white.